Autres langues PTC Therapeutics, Inc.

Actions

PTCT

US69366J2006

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 01/10/2026			Varia. 5j.	Varia. 1 janv.
64,13 ^USD	-1,00%		+2,87%	-15,57%

21/09	PTC Therapeutics finalise l'acquisition de la thérapie génique ST-920 pour la maladie de Fabry	MT
21/09	PTC Therapeutics, Inc. (NasdaqGS:PTCT) a finalisé l’acquisition de ST-920, une thérapie génique AAV administrée en une seule fois et au stade BLA, auprès de Sangamo Therapeutics, Inc. (OTCPK:SGMO.Q).	CI

Autres langues

25/09	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21/09	PTC Therapeutics Closes Acquisition of the ST-920 Gene Therapy for Fabry Disease
21/09	PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
21/09	PTC Therapeutics, Inc. completed the acquisition of ST-920 ? a BLA-stage one-time administered AAV gene therapy from Sangamo Therapeutics, Inc. (OTCPK:SGMO.Q).
27/08	PTC Therapeutics to Participate in Upcoming Investor Conferences
24/08	Ptc Therapeutics Announces New Sephience Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as Well as Consistent Favorable Safety Profile
24/08	PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
12/08	PTC Therapeutics, Inc. proposed to acquire ST-920 ? a BLA-stage one-time administered AAV gene therapy from Sangamo Therapeutics, Inc. (OTCPK:SGMO.Q) for approximately $210 million.
30/07	PTC Q2 Swings to Profit, Revenue Rises; Ups Guidance
30/07	PTC Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2026
30/07	(PTCT) PTC Therapeutics Expects Full Year 2026 Revenue Range $1.18B - $1.28B, vs. FactSet Est of $1.18B
30/07	Earnings Flash (PTCT) PTC Therapeutics Posts Q2 EPS $0.92, vs. FactSet Est of $0.24
30/07	PTC Therapeutics: Q2 Earnings Snapshot
30/07	Earnings Flash (PTCT) PTC Therapeutics, Inc. Reports Q2 Revenue $360.5M, vs. FactSet Est of $298.6M
30/07	PTC Therapeutics, Inc. Announces Appointment of Hege Sollie-Zetlmayer to Board of Directors, Effective July 28, 2026
30/07	PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
30/07	PTC Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
27/07	PTC Therapeutics' Phenylketonuria Physician Survey Yielded Mixed Results on Sephience Launch Momentum, RBC Says
29/06	PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 2000 Value-Defensive Index
29/06	PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 2000 Growth-Defensive Index
29/06	PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 2000 Defensive Index
17/06	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/06	PTC Therapeutics Prices $500 Million Notes Offering
16/06	PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
15/06	PTC Therapeutics Plans $500 Million Convertible Notes Offering to Refinance 2026 Notes